Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oligoDOM messenger RNA
- Development stage
- Preclinical
- Lead developer
- Osivax
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous, Intravenous, Intradermal, Intranodal, Intranasal
01
Overview
oligoDOM messenger RNA is a preclinical mRNA vaccine program developed by Osivax, potentially in partnership with KM Biologics. The platform utilizes Osivax's proprietary oligoDOM® technology, which involves a self-assembling nanoparticle scaffold designed to trigger potent T-cell responses. By combining mRNA technology with the oligoDOM platform, the program aims to develop vaccines for applications in immuno-oncology and infectious diseases. The oligoDOM scaffold is highly versatile and can be used with various antigens to enhance the immune response, specifically targeting the induction of cellular immunity. While Osivax's lead clinical candidates use recombinant protein formulations, this program represents the company's efforts to apply their nanoparticle technology to mRNA-based delivery systems.
- Other names
- oligoDOM messenger RNA
Beyond the preview
Go deeper on oligoDOM messenger RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oligoDOM messenger RNA.